PROTECTING SMALL BUSINESS, PROMOTING ENTREPRENEURSHIP

Importing Price Controls: Making a Bad Situation Far Worse

By at 3 April, 2025, 7:34 am

Small Business Policy Insider

 

by Raymond J. Keating –

Recently, some policy advocates and activists have argued that the way to counter the ills of price controls imposed on prescription drugs and medicines by other countries is to import those price controls into the United States. In fact, these proposals, if inflicted, would mean a major ramping up of price controls in the U.S. – from starting to unlock the door to price controls via the Inflation Reduction Act (IRA), which was signed into law by President Biden in 2022, to blowing the price controls door off its hinges. Let’s hope that Congress and the Trump White House in no way follow such mistaken and dangerous advice.

The economics of price controls are straightforward. When the government steps into the marketplace to impose price controls, actual and potential returns are limited, incentives to invest in the price-controlled industry are reduced, and entrepreneurship, investment, innovation, supply and quality suffer accordingly.

When price controls are applied to the pharmaceuticals, biotechnology and/or medical device industries the results rank as particularly grave, with fewer new and improved medical treatments. Therefore, the costs aren’t limited to lost businesses, investment and jobs, which certainly are bad enough, but such controls also mean lost and shortened lives, and diminished health overall. Price controls on prescription drugs and medicines are a surefire path to increased human suffering.

Criticisms of price controls imposed by other nations are warranted. Citizens of those nations suffer, as do patients in the U.S. and across the world, due to the resulting diminished investment and innovation regarding life-saving and life-enhancing drugs.

For good measure, insurance companies, government programs and patients in those nations, by not paying market prices that, in part, reflect the risks, uncertainties and costs of developing new treatments, get to partially free ride on the investments made in the United States. However, it makes no sense to take the grim problems with price controls in other nations, and importing and inflicting them on U.S. pharmaceutical firms. Quite frankly, it’s all bizarre.

Indeed, some of the advocates for importing price controls seem to think that American firms can simply reject price controls in other nations, and therefore, charge more for their drugs and medicines in those nations, thereby eliminating the price differential between what consumers pay in those nations and what’s paid in the United States. But it’s ridiculous to think that prescription drug companies have any control over the price of their products under a regime of price controls.

Prescription drug firms are under government dictates, and if they even tried to withdraw from the market, those nations’ politicians have the ability to revoke patents – that is, steal the intellectual property of such businesses – and/or impose massive fines. That’s pretty darn close to socialism.

Advocates for importing price controls must understand these simple facts, so their arguments don’t really seem to be about getting other nations to eliminate their price controls, but instead, would appear to be about trying to dress up or disguise their own advocacy for price controls in the U.S.

So, while these advocates for price controls seem to recognize the ills of price controls, they go on to argue for importing price controls via government programs, such as Medicare and Medicaid, as well as on private insurance. Again, this would take the ills of price controls in other nations and the problems starting under Biden’s IRA, and blowing the doors open.

Another avenue offered by these activists in response to price controls in other nations would be to impose tariffs on imports from those nations. That, of course, would simply create additional harms on American businesses and consumers who would pay for such tariffs via increased costs and prices; diminished choices; and slower economic growth.

The arguments for importing price controls and/or imposing tariffs in response to price controls in other nations turn out to be completely detached from economic and business realities – indeed, detached from basic common sense.

Let’s return to reality and review some key points and findings, as SBE Council has done before, regarding the development of new and improved drugs and medicines in the U.S.:

● A Costly and Uncertain On-Ramp to Market. Regarding the costs of bringing a drug to market, a 2021 Congressional Budget Office report summed up: “Developing new drugs is a costly and uncertain process, and many potential drugs never make it to market. Only about 12 percent of drugs entering clinical trials are ultimately approved for introduction by the FDA. In recent studies, estimates of the average R&D cost per new drug range from less than $1 billion to more than $2 billion per drug. Those estimates include the costs of both laboratory research and clinical trials of successful new drugs as well as expenditures on drugs that do not make it past the laboratory-development stage, that enter clinical trials but fail in those trials or are withdrawn by the drugmaker for business reasons, or that are not approved by the FDA.”

● Massive Investment Required. As for levels of investment, it also was noted in the CBO report: “The pharmaceutical industry devoted $83 billion to R&D expenditures in 2019… That amount is about 10 times what the industry spent per year in the 1980s, after adjusting for the effects of inflation. The share of revenues that drug companies devote to R&D has also grown: On average, pharmaceutical companies spent about one-quarter of their revenues (net of expenses and buyer rebates) on R&D expenses in 2019, which is almost twice as large a share of revenues as they spent in 2000. That revenue share is larger than that for other knowledge-based industries, such as semiconductors, technology hardware, and software.”

● The Ills of Price Controls and Investment. Regarding diminished investment in the pharmaceutical industry due to price controls, in a November 2021 study, for example, Vital Transformation noted: “Previous research has shown a decline in biopharma industry investment in Europe relative to the United States, corresponding to increasing price controls in European countries.” The study found that “every 10% drop in the price of medicines in price-controlled EU markets” was associated with a “14% decrease in total VC funding (10% early stage and 17% late stage),” a “7% decrease in biotech patents,” a “9% decrease in biotech start-up funding relative to the US, and an “8% increase in the delay of access to medicines.” In addition, “by 2019, late-stage venture capital funding in the European Union was just 3% of the level in the United States”; “from 2003 to 2019, biotech investments in the United States increased sixfold, while they remained static in the European Union”; and “in 2020, the U.S. share of total annual biotech startups was roughly three times greater than the EU share.”

● The U.S. Environment and Innovation. The U.S. has been the global leader in pharmaceuticals due in large part to its lack of price controls. According to a December 2022 report from Vital Transformation, “60% of FDA approved medicines from 2011- 2020 originated in the United States.” Of the 363 new medicines approved, “the US was solely responsible for the origination of 223 of those medicines.” The CBO also pointed out: “The number of new drugs approved each year has also grown over the past decade. On average, the Food and Drug Administration (FDA) approved 38 new drugs per year from 2010 through 2019 (with a peak of 59 in 2018), which is 60 percent more than the yearly average over the previous decade.”

Small Firms are Dominant. For good measure, as for those who, for some reason, would be on board with price controls based on the notion that this is all about “Big Pharma,” not only does the size of the businesses involved have nothing to do with the ill effects of price controls, but the assumption that this is what the industry is all about is nothing but political assumptions or, even worse, purposefully misleading politics. The reality is that importing price controls, and the resulting negatives for investment, will overwhelming hit smaller firms.

The pharmaceutical and medicine manufacturing sector is overwhelmingly populated by smaller businesses, as noted in the following chart (employer firms).

The role that these small firms play is critical. The December 2022 Vital Transformation study found that “55% of all therapies that the US originated were developed by small biopharma firms with less than $500 mil in annual revenue. Further, 45% were fully discovered by small biopharma firms on their own, without an academic or government transfer of IP.”

The CBO explained the crucial role of smaller businesses quite well: “Small drug companies (those with annual revenues of less than $500 million) now account for more than 70 percent of the nearly 3,000 drugs in phase III clinical trials. They are also responsible for a growing share of drugs already on the market: Since 2009, about one-third of the new drugs approved by the Food and Drug Administration have been developed by pharmaceutical firms with annual revenues of less than $100 million. Large drug companies (those with annual revenues of $1 billion or more) still account for more than half of new drugs approved since 2009 and an even greater share of revenues, but they have only initiated about 20 percent of drugs currently in phase III clinical trials.”

A Productive Policy Response

Rather than seeking to import price controls from other nations, policymakers should put a stop to the price controls being inflicted via Biden’s Inflation Reduction Act (IRA). The law allows the federal government to set the price of certain prescription drugs for Medicare. The first set of price controls is due to be imposed in 2026, with annual additions subsequently. If firms fail to comply, excise taxes will be imposed on their drug sales.

Congress and the Trump White House shouldn’t be looking for ways to expand the imposition of price controls, but if they want to see U.S. leadership and entrepreneurship continue in providing life-saving, life-extending treatments, then they need to repeal the price controls imposed via the Biden IRA.

The next step would be to engage in trade negotiations with other nations to reduce barriers to free trade, including the removal of price controls on prescription drugs. International trade doesn’t occur between nations, but instead between individuals and businesses, and voluntary transactions across town or across international borders create value, and help drive economic and income growth.

The U.S. helps to provide a foundation for entrepreneurship, investment and innovation when it stands up, domestically and internationally, against government burdens like price controls and higher taxes, including tariffs. When the U.S. reduces its own governmental burdens placed on the pharmaceutical industry, and makes the case for other nations to do the same, the health and well-being of individuals at home and around the globe benefit enormously.

Raymond J. Keating is chief economist for the Small Business & Entrepreneurship Council. He is the author of “The Weekly Economist” book series, and 10 Points from Walt Disney on Entrepreneurship.

 

News and Media Releases